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Objective: The present study is focused on optimization of elastic liposomes-in-vehicle 
formulations in respect to drug release and formulation properties. By combining penetration 
potential of elastic liposomes containing high ratio of entrapped drug and physicochemical 
properties of vehicles, both affecting the release and texture properties, optimal formulation 
could be achieved. 
Materials and methods: Deformable, propylene glycol-containing or conventional liposomes 
with hydrophilic model drug (diclofenac sodium) were incorporated into the following 
vehicles appropriate for skin application: a hydrogel, a cream base and derma membrane 
structure base cream (DMS base). Each formulation was assessed for in vitro drug release and 
mechanical properties.  
Results and discussion: The composition and type of both liposomes and the vehicle affected 
the rate and amount of the released drug. The cream base exhibited the slowest release, 
followed by the hydrogel and DMS base. Similar release profiles were achieved with both 
types of elastic vesicles (deformable and propylene glycol liposomes); the slowest release was 
observed for conventional liposomes, regardless of the vehicle used. The drug release profiles 
from different liposomes-in-vehicle formulations were in agreement with the physicochemical 
properties of the formulations. All of the liposomes were found to be compatible with the 
hydrogel preserving its original textures, whereas a significant decrease in all texture 
parameters was observed for liposomes-in-DMS base, regardless of liposome type. 
Conclusion: Propylene glycol liposomes-in-hydrogel is considered as the optimal formulation 
for improving skin delivery of hydrophilic drug. Further investigations involving in vivo 





Effective (trans)dermal drug delivery depends on both the selection of an appropriate drug 
and the properties of the delivery system (vehicle). Vehicles exert pronounced effects on the 
epidermis, affecting hydration, lubrication, drying, skin smoothness, occlusion and protection. 
In addition, the physicochemical properties of vehicles influence the pharmacokinetic 
properties of the incorporated drug by controlling its release from the vehicle and affecting 
penetration through the stratum corneum, permeation through the layers of skin and 
absorption into the blood. Therefore, interactions between the vehicle, skin and drug can 
influence the final therapeutic effect of the applied formulation
1,2
. For this reason, the 




Despite the numerous types of available vehicles, dermal and particularly transdermal 
delivery of hydrophilic drugs is limited by the barrier nature of the outermost layers of the 
epidermis. Various strategies have been explored to enhance transdermal drug delivery, 
including adjustment of stratum corneum permeability by chemical penetration enhancers and 
electrical/external force methods, such as iontophoresis, sonophoresis and electroporation
5
. 
During the last two decades, considerable attention has been focused on developing 
nanodelivery systems that facilitate changes of the pharmacokinetic properties of a given drug 
and increase its bioavailability
6
. Because they are physiologically acceptable, phospholipid 
vesicles (liposomes) have shown great potential for improving the topical delivery of 
hydrophilic drugs. While conventional liposomes generally enhance skin deposition of the 
drug without affecting percutaneous permeation and transdermal delivery
7
, new classes of 







 and propylene glycol-containing liposomes
13
, have been shown to increase the 
transport of active substances through the stratum corneum into the deeper layers of skin and 
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even transdermally. Despite these advantages, topical application of liposomes can be 
restricted by their liquid nature. Thus, they must be incorporated into a suitable vehicle
14
. In 
addition to increasing the viscosity and preserving physical stability of conventional 
liposomes incorporated into hydrogels
15-18
, dermatological vehicles could affect drug 
bioavailability and play an important role in the care and maintenance of skin health
2
.  
In the previous study
19
, we optimized the preparation conditions and evaluated the skin 
penetration potential of the two types of elastic liposomes containing a hydrophilic model 
drug (diclofenac sodium) using the stratum corneum-like pohospholipid vesicle-based 
permeation assay. Continuing this line of research, here we report on the optimization of 
semi-solid vehicles for liposomes. To the best of our knowledge, this is the first study which 
examines the influence of different types of vehicles on drug release and texture profiles of 
elastic liposomes in vehicle formulations. Deformable and propylene glycol as elastic 
liposomes and conventional liposomes (as control) were mixed into the following three 
vehicles: a hydrogel, a cream base (oil in water emulsion, O/W) and a novel cream-like 
vehicle that had a composition resembling natural human skin components. Each of these 
formulations (liposomes-in-vehicle) was tested for the drug release and characterized 






2. MATERIALS AND METHODS 
2.1. Materials 
Soy lecithin (S 75) and derma membrane structure base cream classic (DMS base) were 
generous gifts from Lipoid GmbH (Ludwigshafen, Germany) and KOKO GmbH 
(Leichlingen, Germany), respectively. Carbopol 980 NF and diclofenac sodium were kindly 
provided by BF Goodrich (Brussels, Belgium) and PLIVA Croatia Ltd. (Zagreb, Croatia), 
respectively. Sodium deoxycholate, Tween 60, glycerol monostearate, Myglyol 812 N and 
agarose were purchased from Sigma-Aldrich Company (St. Louis, USA). Propylene glycol, 
triethanolamine, cetylalcohol and vaselinum album were purchased from Kemig (Zagreb, 
Croatia). Ethanol and methanol were of analytical grade and obtained from Kemika (Zagreb, 
Croatia). 
 
2.2. Preparation and characterization of liposomes 
Deformable, propylene glycol and conventional liposomes were prepared by the film 
hydration method, followed by extrusion, as previously described
19
. Briefly, lipid components 
were dissolved in concentrated ethanol in a round bottomed flask. The ethanol was removed 
using a rotary vacuum evaporator (Büchi Rotavapor R-200, Büchi Labortechnik AG, Flawil, 
Switzerland) and the thin lipid film was hydrated with the aqueous drug solution. The 
concentrations of the lipid (26 mM) and diclofenac sodium (47 mM) were kept constant for 
all liposome preparations. Conventional liposomes were composed of S 75. The deformable 
liposomes consisted of S 75 and sodium deoxycholate (85/15, mass ratio), and the propylene 
glycol liposomes contained the same bilayer composition as conventional liposomes with an 
additional 10% (w/w) propylene glycol in an aqueous phase. All of the liposomes were 
extruded three times through the 400-nm pore size polycarbonate membranes (LiposoFast, 
Avestin, Canada).  
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The mean diameters, size distributions (polydispersity) and zeta potentials of the liposomes 
were determined by photon correlation spectroscopy (Zetasizer 3000HS, Malvern 
Instruments, Malvern, UK)
20,21
. Membrane elasticity of extruded liposomes was evaluated by 
home-made device at an external pressure of 5 bar using 100-nm membranes. Detailed 
procedure with equation for calculation of the deformability degree (E) has been previously 
described in details
14,19
. Separation of the unentrapped drug was performed using gel 
chromatography on Sepharose CL-4B
22
. Thereafter, the liposomal fraction was concentrated 
using ultracentrifugation as previously described
19
. The concentrations of both the 
unentrapped (free) and liposome-entrapped drug were determined spectrophotometrically 
(Ultrospect Plus, Pharmacia LKB, Cambridge, UK). The concentrations of free diclofenac 
sodium were measured at 276 nm (demineralized water), and the entrapped drug was detected 
at 282 nm after the liposomes were dissolved in methanol. 
 
2.3.  Preparation of semi-solid vehicles 
2.3.1. Hydrogel 
Carbopol 980 NF (0.5 g) was dispersed in demineralized water (88.5 g) using a magnetic 
stirrer (700 rpm) for 60 minutes. Propylene glycol (10 g) was then added, and the mixture 
neutralized by the addition of 50% (w/w) triethanolamine in an amount sufficient to achieve a 
gel of pH 6
23
. 
2.3.2. Cream base 
The cream base was an oil-in-water (O/W) emulsion prepared using the modified procedure 
of Betz and coworkers
24
. Briefly, the lipophilic phase components [glycerol monostearate (4 
g), cetylalcohol (6 g), Miglyol 812 (7.5 g), vaselinum album (25.5 g)] and hydrophilic phase 
components [Tween 60 (6.5 g), propylene glycol (10 g), distilled water (40.5 g)] were 
separately heated to 60 C using a water bath. The oil phase was then gradually poured into 
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the water phase with constant stirring by hand to form an emulsion that was stirred until the 
cream reached room temperature. The formed O/W emulsion was subjected to 
homogenization by a Three Roller Mill (Erweka SM/SMS, Erweka GmbH, Heusenstamm, 
Germany). 
 
2.4.  Incorporation of liposomes into vehicles 
Each of the liposome suspensions (deformable, propylene glycol or conventional liposomes) 
containing only liposomally-entrapped diclofenac sodium and free of unentrapped drug, was 
gently mixed into the vehicles: hydrogel, cream base or DMS base.  
The final concentration of liposomes in the vehicle was 10% (w/w, liposome 
suspension/vehicle). Control samples (solution of the free drug incorporated in vehicle, 10% 
w/w, drug solution/vehicle) contained the same concentration of the drug as in the liposomes. 
 
2.5.  In vitro drug release studies 
The release of the drug from the liposomes incorporated into different vehicles was 
determined by the method originally introduced by Pesckha et al.
25
 and adapted for liposomal 
hydrogels
14,16,23
. Briefly, samples of the liposomes-in-vehicle formulations (3 g) were placed 
in glass vials and separated from 5 mL of receptor solution (distilled water) by a 2% (w/w) 
agarose layer, which permitted diffusion of both the released drug and intact liposomes from 
liposomes-in-vehicles (donor compartment). The vials were incubated at 32 °C, and the 
receptor solution was completely replaced at specific time intervals. The amount of the drug 
released was determined spectrophotometrically (before and after the addition of methanol). 
Controls were examined under the same conditions. 




2.6. Texture analysis of the liposomes-in-vehicle formulations 
A Texture Analyzer TA.XT Plus (Stable Micro Systems Ltd., Surrey, UK) was used to 
examine the texture properties of the liposomes-in-vehicle formulations. Fifty grams of each 
formulation was placed in a standard beaker, ensuring that no air bubbles were included and 
that the surface was smooth. A disk (40 mm in diameter) was pushed into the formulation (10 
mm at a speed of 1 mm/s, respectively) and removed. Each formulation was measured five 
times, ensuring the same conditions for each measurement. The hardness of the each 
formulation was determined, and the texture properties, such as cohesiveness and 
adhesiveness, were calculated
26
. Control samples were examined under the same conditions. 
 
2.7. Statistical analysis 
Statistical analysis was performed using a one-way ANOVA, followed by Tukey’s 
multiparametric post hoc test, and p < 0.05 was considered the minimum level of significance. 
Calculations were performed with the GraphPad Prism program, version 5.01 (GraphPad 
Software, Inc., San Diego, CA). 
 
3. RESULTS AND DISCUSSION 
3.1. Characterization of liposomes 
Composition of the liposomes used as topical drug carrier is known to influence their 
physicochemical properties and therefore their efficacy as drug delivery system
27,28
. To allow 
deeper penetration of the hydrophilic drug into/through the skin, we prepared two types of 
elastic liposomes and compared them with each other and with conventional liposomes with 
respect to the following physicochemical properties: size, charge, membrane elasticity and 
entrapment capacity for diclofenac sodium (Table 1). The conventional and propylene glycol 
liposomes were nearly the same size and characterized by a homogenous size distribution, 
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with a mean diameter between 155 (conventional liposomes) and 160 nm (propylene glycol 
liposomes), while the deformable liposomes were slightly smaller (143 nm) than the others. 
The presence of the edge activator (sodium deoxycholate) in the bilayers of deformable 
liposomes increased membrane flexibility and reduced surface tension, which are 
recognizable features of elastic liposomes, as shown in recent studies
14,21,29,30
. Drug 
entrapment was quite low in the deformable liposomes (60 g of the drug/mg of lipid 
recovered), as compared to the propylene glycol liposomes (>140 g/mg of lipid). In addition, 
propylene glycol increased the degree of membrane elasticity, which was nearly equal to that 
of the deformable liposomes (Table 1). This result may be explained by the ability of 
propylene glycol to solubilize phospholipids and intercalate into the bilayer
13,31,32
, affecting 
the membrane flexibility of the vesicles. Regarding the surface charge, all of the liposomes 
had highly negative zeta potentials (> -50 mV), indicating the formation of physically stable 




3.2.  Liposomes-in-vehicle formulations 
Appropriate viscosity of liposomes used for skin application can be achieved by incorporation 
into dermatological vehicles
15
. Vehicle composition has been shown to influence the release 
properties of the incorporated drug and the penetration ability across/into the skin and may 
also improve the skin condition
3,4,33
. To examine the effect of the vehicle on the release of 
liposomally entrapped diclofenac sodium, different types of liposomes were incorporated into 
the following vehicles: the hydrogel, the cream base (O/W emulsion) and DMS base.  
To follow the release of diclofenac sodium from the liposomes-in-vehicle formulations, we 
applied a so-called agarose method that has been shown to be very useful in evaluating drug 
release from liposomal vaginal gels
14,16,23
. The porosity of the agarose matrix permitted both 
intact liposomes and released (free) drug to diffuse through the matrix into the receptor 
10 
 
solution, and the amount of drug released from the vehicle was determined 
spectrophotometrically before and after the addition of methanol to the supernatant over the 
agarose matrix
16
. With this method, the amount of intact liposomes released from the vehicle 
into the receptor medium can be determined, which is not feasible using the Franz diffusion 
cell method. Moreover, this method provides insight into the possible mechanisms of drug 
release from liposomes-in-vehicle formulations, which have been proposed to be based on the 
following four interconnected processes: leakage of the drug inside the vehicle, diffusion of 
the released drug to the receptor compartment, diffusion of intact liposomes from the vehicle 




The release of diclofenac sodium from the various liposomes-in-vehicle formulations is 
presented in Table 2 and Figure 1. The results (Table 2) confirm slower release of the drug 
from all of the liposomes-in-vehicle formulations compared with the control (solution of the 
drug in vehicle), and compared to the drug release from liposomal suspensions
19
. Differences 
in the drug release profiles were observed between all of the liposomes and vehicles 
examined. The slowest release of diclofenac sodium was observed for the cream base, 
followed by the hydrogel and DMS base (Table 2). Interestingly, release of the drug from 
liposomes-in-DMS base followed the same profile as corresponding control indicating 
possible release of the drug from all the liposomes upon their mixing into DMS base. A 
comparison of the drug-release profiles from different types of liposomes incorporated in 
hydrogel or cream base confirmed the slowest release from conventional liposomes in both 
cases; the drug release from propylene glycol liposomes and especially deformable vesicles 
was significantly faster (p < 0.05).  These results were in agreement with the previous study
19
, 
where the highest release of the drug was achieved from deformable, followed by propylene 
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glycol-containing liposomes, while the slowest release was demonstrated by conventional 
liposomes. 
The release of diclofenac sodium from all of the investigated formulations followed the 
Higuchi diffusion model
35
, which was confirmed by the good correlation coefficients ranging 
from 0.988 to 0.995 (Figure 1). This finding indicates that the rate-controlling step in the 
release process was the diffusion of the leaked drug through the vehicle network to the 
receptor medium, which was affected by both the composition of the phospholipid vesicles 
and the mechanical properties of the vehicles. Thus, after 24 hours of incubation of liposomes 
in hydrogel at 32 °C, more than 35% of the drug was released from each formulation of 
elastic vesicles, while the lowest ratio of released drug (28%) was observed for the 
conventional liposomes (p < 0.05).  
Although the fastest drug release profile from the liposomes-in-vehicle formulations was with 
DMS base, the highest release of the solution of the drug in vehicle (control) was achieved 
with the hydrogel (p < 0.05). These results were expected to some extent given the 
hydrophilic properties of both the drug and the hydrogel. Diclofenac sodium has a 
dissociation constant (pKa) of 3.9 at 25 °C in water and a log P of 1.45
36
. The hydrogel used 
in this study contained 89% water and 10% propylene glycol, which acts as both a humectant 
and a skin-penetration enhancer. Therefore, encapsulation into liposomes extended the release 
of the drug from the hydrogel.  
An evaluation of intact liposome release from the hydrogel and the cream base showed a 
similar release ratio of both deformable and propylene glycol liposomes compared with 
conventional liposomes (p < 0.05), which can be attributed to effect of the degree of 
membrane elasticity of the vesicles (Table 1) on the penetration of the liposomes through the 
vehicle and agarose matrix into the receptor solution (Table 2). Although propylene glycol 
liposomes had the same bilayer composition as conventional liposomes, they contained 
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propylene glycol, a well-known skin-penetration enhancer
37,38
 that has been shown to 
contribute to membrane elasticity (Table 1), and subsequently affected the penetration of the 
liposomes through the vehicle network into the receptor medium. These results were 
consistent with those of a recent investigation
14
 that demonstrated the significance of vesicle 
composition on the drug-release profile from the hydrogel. Thus, liposomes with pronounced 
elastic properties diffused more rapidly through the hydrogel network than conventional 
liposomes
14
. Given that the intended route of administration of the drugs in liposomes-in-
vehicle formulations is through the skin, penetration of the drug through the stratum corneum 
is of great importance. An assessment of the different classes of liposomes (deformable, 
propylene glycol and conventional liposomes) using a novel stratum corneum-like 
phospholipid vesicle-based permeation assay
19
 demonstrated that propylene glycol liposomes 
were the most promising formulation for improving the topical delivery of diclofenac sodium.  
 
The success of dermatotherapy depends also on the properties of the formulation, particularly 
the spreading ability and retention of the formulation on the skin
18
. Texture analysis was used 
to evaluate the mechanical properties of the different liposomes-in-vehicle formulations, and 
parameters such as hardness, adhesiveness and cohesiveness were assessed (Figure 2). These 
properties have been directly correlated with administration parameters in vivo, such as 
spreadability (hardness) and retention of the formulation on the skin (adhesiveness) or its 
removal from the container (cohesiveness)
14,26
. Therefore, these investigations are of major 
importance during the development and optimization of formulations. In addition, they 
provide valuable data on the compatibility of the incorporated liposomes with the vehicle.  
As shown in Figure 2, the texture characteristics were significantly different between all of 
the examined vehicles. The cream base showed highest values of all of the parameters 
assessed, followed by the hydrogel and DMS base. The cream base used in this study 
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contained vaselinum album and cetylalcohol, which were responsible for the hardness of the 
formulation. Mixing the liposomes in the cream base significantly (ANOVA, p < 0.05) 
lowered the initial hardness by approximately 30% for the conventional and propylene glycol 
liposomes and slightly more for the deformable liposomes (35%) (Figure 2 A).  
Conventional liposomes have already been proven to be compatible with Carbopol gels
15,23
. 
Stability of liposomes incorporated in vehicle, especially emulsion and lamellar types of 
vehicle could be influenced by the vehicle’s ingredients. DMS base is a novel cream-like 
vehicle used in corneotherapy that is prepared without classic emulsifiers and contains lipids 
similar to those found in human stratum corneum. It is composed of hydrogenated soy 
phosphatidylcholine, medium chain trigylcerides, phytosterols and squalane
39
. Clinical studies 
have confirmed increased levels of skin hydration and reparation of disrupted skin barriers 
with DMS base when used alone or with incorporated active ingredients
39,40
. Although it has 
been shown that liposomally encapsulated active compounds mixed in DMS base can 
significantly improve skin conditions (more than free active compounds in the vehicle)
39
, our 
results, which were based on texture analysis, indicate a possible physical instability of 
liposomes in DMS base. A nearly 2-fold decrease of the initial hardness was observed after 
incorporation of the liposomes into DMS base (more than 60%, regardless of the type of 
liposome). In contrast, mixing a solution of the free drug (control) into DMS base reduced the 
initial hardness by only 20% (Figure 2A). Therefore, we speculate that there may be an 
interaction/incompatibility between all of the types of liposomes used in this study and DMS 
base, likely caused by the interaction of the negatively charged soy lecithin (S 75) liposomes 
with the ingredients of the DMS base, predominantly hydrogenated phospholipids. The 10% 
of liposomes in DMS base (w/w) represent relatively high source of the negative surface 
charge in the vehicle, probably causing the disturbance within the lamellar structure of DMS 
base. This assumption was also supported with release studies in which the ratio of intact 
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liposomes released was lower than 1%, even after 24 hours (Table 2). To verify the 
interactions/compatibility of liposomes with the components of the DMS vehicle, further 
studies based on hydrogenated soy phosphatidylcholine liposomes would be valuable. 
The smallest decrease in the original hardness was observed with liposomes in the hydrogel. 
Thus, all liposomes are compatible with the hydrogel (p > 0.05). These results are consistent 
with observations concerning Carbopol gels that were recently reported by Hurler and Škalko-
Basnet
41
 and Vanić and collaborators
14
, in which liposomes preserved the original structure of 
the gels. The other two texture parameters (cohesiveness and adhesiveness) followed similar 
patterns for the examined liposomes-in-vehicle formulations (Figure 2B and C).  
Vehicle composition has been shown to play an important role in spreading and retaining the 
formulation at the application site
42
 and in the release profile of the incorporated drug
4
. 
Phospholipid vesicles with pronounced elastic properties have been demonstrated to 
considerably improve transdermal delivery of hydrophilic drugs
7,8,43
. By combining 
penetration potential of elastic liposomes containing high ratio of entrapped drug and 
physicochemical properties of vehicles, both affecting the release and texture properties, 
optimal formulation could be achieved. Therefore, propylene glycol liposomes in a hydrogel 




Deformable, propylene glycol and conventional liposomes containing diclofenac sodium were 
incorporated into different vehicles appropriate for skin application and characterized by in 
vitro drug release and texture parameters. The release of the drug from the different 
liposomes-in-vehicle formulations was affected by the composition of the vesicles and the 
mechanical properties of the vehicles. All types of liposomes preserved the original texture of 
15 
 
hydrogel. Based on these studies, propylene glycol liposomes-in-hydrogel is the most suitable 
formulation due to the favorable physicochemical properties of liposomes, high trapping 
efficiency, the drug release profile from the vehicle, the ratio of intact liposomes released and 
the protective mechanism of the hydrogel on liposomes. However, to confirm the superiority 
of the proposed formulation for the skin therapy, animal studies would be beneficial. 
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Table 1. Physicochemical properties of liposomes  
 
Parameter DL PGL CL 
Mean diameter (nm) 143.3 ± 5.1 159.7 ± 3.4 156.1 ± 2.6 
Polydispersity index 0.28 ± 0.05 0.20 ± 0.07 0.19 ± 0.02 
Zeta potential (mV) -56.3 ± 0.7 -61.4 ± 1.1 -58.4 ± 0.8 
Degree of 
deformability, E 
5.58 ± 0.33 5.23 ± 0.31 1.08 ± 0.11 
Entrapment 
(drug/lipid, g/mg) 
60.3 ± 2.8 142.8 ± 4.2 129.4 ± 3.5 
DL – deformable liposomes;  PGL – propylene glycol liposomes; 
CL – conventional liposomes 
The values denote the mean  S.D. (n=3). 
20 
 
Table 2. In vitro release of diclofenac sodium from various liposomes-in-vehicle formulations 
t 
(h) 
Hydrogel  Cream base  DMS base 
DL  PGL CL  Control 
 
DL  PGL CL  Control 
 
DL  PGL CL  Control 
1 
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4.4 ± 0.5 
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0.5 ± 0.2 c 
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76.9 ± 7.1 
DL – deformable liposomes;  PGL – propylene glycol liposomes; CL – conventional liposomes; 
a
 free drug released (%); 
b
 total drug  released (%); 
c
 drug in intact 
liposomes released (%) 
Samples of liposomes-in-vehicles containing diclofenac sodium were incubated at 32 °C in distilled water (for details, see section 2.5.). The amount of the drug in the release 
media was determined before (free drug) and after (total drug) disruption of the released liposomes with methanol. The difference between the total and the free drug released 
indicates the amount of the drug still present in the liposomes and released from the vehicle into the receptor solution (intact liposomes with drug). Control experiments 






Figure 1.  















































































































































































































































































































































Figure 1. Cumulative release of diclofenac sodium from various liposomes-in-vehicle 
formulations plotted according to Higuchi
35
 equation: liposomes-in-hydrogel (A), liposomes-
in-cream base (B), liposomes-in-DMS base (C). The amounts of the released drug were 
detected in receptor media before addition of methanol (DL – deformable liposomes; PGL – 
propylene glycol liposomes; CL – conventional liposomes). The values denote the mean  
S.D. (n = 3). The values without error-bars have standard deviation equal or smaller than the 
size of the symbols. 
 
Figure 2. Influence of liposome types on the texture properties of vehicles: hardness (A), 
cohesiveness (B) and adhesiveness (C). Empty sample denotes original vehicle, while control 
sample indicates a solution of the drug incorporated in vehicle. CL, DL and PGL represent 
different types of liposomes in vehicle. Concentration of the free drug and liposomes in 
vehicles was kept constant for all the samples (10% w/w, solution of free drug or 
liposomes/vehicle). The values indicate the mean ± S.D (n=5). 
 
 
 
